ETF盘中资讯 港股创新药继续调整，龙头股普跌，场内宽幅溢价！最新消息：中国药品价格登记系统上线

Group 1 - The Hong Kong innovative drug sector continues to adjust, with leading stocks like BeiGene, Innovent Biologics, and CSPC Pharmaceutical all dropping over 1%, while China Biologic Products and 3SBio fell more than 2% [1] - The Hong Kong Stock Connect Innovative Drug ETF (520880) has over 70% of its holdings in leading innovative drug stocks, experiencing a decline of over 1% and marking its fourth consecutive day of decline, despite a persistent premium in the market indicating strong buying interest [1][2] - The launch of China's drug price registration system on December 2 allows domestic and foreign pharmaceutical companies to independently declare drug prices, which is expected to facilitate the globalization of innovative drugs and attract high-quality new drugs into the Chinese market [2][3] Group 2 - Analysts predict that the innovative drug industry will maintain its trend through 2026, with increasing global competitiveness and ongoing international expansion, suggesting a focus on overseas progress of already developed products [3] - The Hong Kong Stock Connect Innovative Drug ETF (520880) is highlighted as the largest in its category, with its index comprising primarily innovative drug companies, excluding CXO firms, and featuring a significant concentration of leading stocks [3][4] - The top ten stocks in the ETF account for over 72% of its weight, showcasing the dominance of leading innovative drug companies [4]